Gary Rothbard, MD, MS, Author at Infectious Disease Advisor

COVID19

ACC Policy Statement on COVID-19 Vaccination Prioritization Based on CVD Considerations

By

Gary Rothbard, MD, MS

April 14, 2021

ACC policy position statement on prioritization and allocation of COVID-19 vaccine focuses on cardiovascular disease.

COVID19

ASAIO Recommendations for Advanced Cardiopulmonary Support for Patients With COVID-19

By

Gary Rothbard, MD, MS

July 10, 2020

Recommendations by ASAIO on the selection and treatment of patients with respiratory and circulatory failure associated with COVID-19 using artificial pulmonary and/or cardiac support.

COVID19

Hydroxychloroquine With or Without Azythromycin for COVID-19 Treatment Associated With Increased Risk for QTc Prolongation

By

Gary Rothbard, MD, MS

May 29, 2020

Patients treated with hydroxychloroquine alone or in combination with azithromycin for pneumonia associated with COVID-19 were found to be at increased risk for corrected QT interval prolongation.

Hepatitis

Comparable Survival With Hepatitis C-Positive, -Negative Heart Transplant Donors

By

Gary Rothbard, MD, MS

January 15, 2020

Patients who received heart transplants from hepatitis C virus-positive vs -negative donors were found to have comparable survival at 1 year and patients who developed transplant-related hepatitis C responded well to treatment.

Gary Rothbard, MD, MS

All articles by Gary Rothbard, MD, MS

ACC Policy Statement on COVID-19 Vaccination Prioritization Based on CVD Considerations

ASAIO Recommendations for Advanced Cardiopulmonary Support for Patients With COVID-19

Hydroxychloroquine With or Without Azythromycin for COVID-19 Treatment Associated With Increased Risk for QTc Prolongation

Comparable Survival With Hepatitis C-Positive, -Negative Heart Transplant Donors

Heart Transplants From HCV-Positive Donors Safe